Bokf Na Reduces Position in Exact Sciences Co. (NASDAQ:EXAS)

Bokf Na decreased its position in Exact Sciences Co. (NASDAQ:EXAS) by 35.7% in the fourth quarter, HoldingsChannel.com reports. The fund owned 19,481 shares of the medical research company’s stock after selling 10,802 shares during the period. Bokf Na’s holdings in Exact Sciences were worth $1,101,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its position in Exact Sciences by 74.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,760,241 shares of the medical research company’s stock worth $323,669,000 after buying an additional 2,462,165 shares during the last quarter. Capital World Investors raised its holdings in shares of Exact Sciences by 10.7% during the fourth quarter. Capital World Investors now owns 17,537,617 shares of the medical research company’s stock worth $985,439,000 after purchasing an additional 1,696,321 shares during the last quarter. Norges Bank acquired a new position in Exact Sciences during the fourth quarter valued at $50,625,000. T. Rowe Price Investment Management Inc. boosted its holdings in Exact Sciences by 25.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,269,823 shares of the medical research company’s stock valued at $239,922,000 after purchasing an additional 876,985 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in Exact Sciences during the 4th quarter worth about $21,251,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Mizuho began coverage on Exact Sciences in a research note on Thursday, April 10th. They issued an “outperform” rating and a $60.00 target price on the stock. Evercore ISI lifted their target price on shares of Exact Sciences from $60.00 to $66.00 and gave the company an “outperform” rating in a report on Friday, May 2nd. Guggenheim reissued a “buy” rating and set a $60.00 price target on shares of Exact Sciences in a report on Friday, April 11th. Royal Bank of Canada lifted their price objective on shares of Exact Sciences from $52.00 to $54.00 and gave the company a “sector perform” rating in a report on Friday, May 2nd. Finally, Bank of America lowered their target price on shares of Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, February 20th. Two investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $70.90.

Exact Sciences Trading Down 0.5 %

Shares of EXAS opened at $53.04 on Friday. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. The firm has a 50-day moving average price of $45.47 and a 200 day moving average price of $52.96. Exact Sciences Co. has a 12-month low of $39.97 and a 12-month high of $72.83. The firm has a market capitalization of $10.01 billion, a P/E ratio of -9.52 and a beta of 0.92.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.16. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The business had revenue of $706.79 million during the quarter, compared to analysts’ expectations of $688.58 million. During the same period in the prior year, the business posted ($0.60) EPS. The company’s revenue was up 10.9% compared to the same quarter last year. Sell-side analysts forecast that Exact Sciences Co. will post -0.58 EPS for the current year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.